Your browser doesn't support javascript.
loading
Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.
Menezes, Shinelle; Okail, Mohamed Hazem; Jalil, Siti Munira Abd; Kocher, Hemant M; Cameron, Angus J M.
Afiliación
  • Menezes S; Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, London, UK.
  • Okail MH; Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, London, UK.
  • Jalil SMA; Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, London, UK.
  • Kocher HM; Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, London, UK.
  • Cameron AJM; Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK.
J Pathol ; 257(4): 526-544, 2022 07.
Article en En | MEDLINE | ID: mdl-35533046
Cancer-associated fibroblasts (CAFs) have conflicting roles in the suppression and promotion of cancer. Current research focuses on targeting the undesirable properties of CAFs, while attempting to maintain tumour-suppressive roles. CAFs have been widely associated with primary or secondary therapeutic resistance, and strategies to modify CAF function have therefore largely focussed on their combination with existing therapies. Despite significant progress in preclinical studies, clinical translation of CAF targeted therapies has achieved limited success. Here we will review our emerging understanding of heterogeneous CAF populations in tumour biology and use examples from pancreatic ductal adenocarcinoma to explore why successful clinical targeting of protumourigenic CAF functions remains elusive. Single-cell technologies have allowed the identification of CAF subtypes with a differential impact on prognosis and response to therapy, but currently without clear consensus. Identification and pharmacological targeting of CAF subtypes associated with immunotherapy response offers new hope to expand clinical options for pancreatic cancer. Various CAF subtype markers may represent biomarkers for patient stratification, to obtain enhanced response with existing and emerging combinatorial therapeutic strategies. Thus, CAF subtyping is the next frontier in understanding and exploiting the tumour microenvironment for therapeutic benefit. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Fibroblastos Asociados al Cáncer Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Pathol Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Fibroblastos Asociados al Cáncer Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Pathol Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido